Related references
Note: Only part of the references are listed.HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models
Dongsheng Wang et al.
CLINICAL CANCER RESEARCH (2017)
Targeting the EGFR T790M mutation in non-small-cell lung cancer
Nicola Normanno et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2017)
Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer
Yoshihisa Kobayashi et al.
MOLECULAR CANCER THERAPEUTICS (2017)
HER2 Transmembrane Domain (TMD) Mutations (V659/G660) That Stabilize Homo- and Heterodirnerization Are Rare Oncogenic Drivers in Lung Adenocarcinoma That Respond to Afatinib
Sai-Hong Ignatius Ou et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer
T. S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
MET receptor inhibition: Hope against resistance to targeted therapies?
Audrey Hochart et al.
BULLETIN DU CANCER (2017)
RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies
Bingliang Fang
ACTA BIOCHIMICA ET BIOPHYSICA SINICA (2016)
HER3/ErbB3, an emerging cancer therapeutic target
Ningyan Zhang et al.
ACTA BIOCHIMICA ET BIOPHYSICA SINICA (2016)
Different EGFR Gene Mutations in Exon 18, 19 and 21 as Prognostic and Predictive Markers in NSCLC: A Single Institution Analysis
Sabrina Rossi et al.
MOLECULAR DIAGNOSIS & THERAPY (2016)
Activating ERBB4 mutations in non-small cell lung cancer
K. J. Kurppa et al.
ONCOGENE (2016)
The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer
Francisco J. Sanchez-Martin et al.
CLINICAL CANCER RESEARCH (2016)
Third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer
Robert Pirker
CURRENT OPINION IN ONCOLOGY (2016)
Drugging the addict: non-oncogene addiction as a target for cancer therapy
Remco Nagel et al.
EMBO REPORTS (2016)
Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutations
Hampig Raphael Kourie et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2016)
RAS isoforms and mutations in cancer at a glance
G. Aaron Hobbs et al.
JOURNAL OF CELL SCIENCE (2016)
Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer
Shuhang Wang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Synchronized Targeting of Notch and ERBB Signaling Suppresses Melanoma Tumor Growth through Inhibition of Notch1 and ERBB3
Keman Zhang et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2016)
Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation
Silvia La Monica et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
BE-POSITIVE: Beyond progression after tyrosine kinase inhibitor in EGFR-positive non small cell lung cancer patients Results from a multicenter Italian observational study
Tiziana Vavala et al.
LUNG CANCER (2016)
The combination of trastuzumab and pertuzumab administered at approved doses may delay development of trastuzumab resistance by additively enhancing antibody-dependent cell-mediated cytotoxicity
Gabor Toth et al.
MABS (2016)
Targeting HER3 using mono- and bispecific antibodies or alternative scaffolds
Magdalena Malm et al.
MABS (2016)
High-throughput imaging: Focusing in on drug discovery in 3D
Linfeng Li et al.
METHODS (2016)
Past, Present, and Future of Targeting Ras for Cancer Therapies
Zhi Tan et al.
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2016)
Correlation of EGFR Del 19 with Fn14/JAK/STAT signaling molecules in non-small cell lung cancer
Ying Sun et al.
ONCOLOGY REPORTS (2016)
Preclinical and clinical studies on afatinib in monotherapy and in combination regimens: Potential impact in colorectal cancer
I. De Pauw et al.
PHARMACOLOGY & THERAPEUTICS (2016)
Three-dimensional culture systems in cancer research: Focus on tumor spheroid model
Sritama Nath et al.
PHARMACOLOGY & THERAPEUTICS (2016)
MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations
Sabrina Arena et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Lapatinib resistance in HER2+cancers: latest findings and new concepts on molecular mechanisms
Huiping Shi et al.
TUMOR BIOLOGY (2016)
Osimertinib making a breakthrough in lung cancer targeted therapy
Haijun Zhang
ONCOTARGETS AND THERAPY (2016)
An anti-ErbB2 fully human antibody circumvents trastuzumab resistance
Qiong Lu et al.
ONCOTARGET (2016)
Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus
Xiaochun Liu et al.
ONCOTARGET (2016)
PA-MSHA in combination with EGFR tyrosine kinase inhibitor: A new strategy to overcome the drug resistance of non-small cell lung cancer cells
Xin-min Zhao et al.
ONCOTARGET (2016)
Uncoupling of EGFR-RAS signaling and nuclear localization of YBX1 in colorectal cancer
F. Rossner et al.
ONCOGENESIS (2016)
Role of targeted therapy in metastatic colorectal cancer
Yoshihito Ohhara et al.
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY (2016)
The Panitumumab EGFR Complex Reveals a Binding Mechanism That Overcomes Cetuximab Induced Resistance
E. Allen Sickmier et al.
PLOS ONE (2016)
The combinatorial approach of laser-captured microdissection and reverse transcription quantitative polymerase chain reaction accurately determines HER2 status in breast cancer
Elisabeth Hofmann et al.
BIOMARKER RESEARCH (2016)
KRAS Mutation as the Biomarker of Response to Chemotherapy and EGFR-TKIs in Patients With Advanced Non-Small Cell Lung Cancer Clues For Its Potential Use in Second-Line Therapy Decision Making
Alma D. Campos-Parra et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2015)
ERBB4 is over-expressed in human colon cancer and enhances cellular transformation
Christopher S. Williams et al.
CARCINOGENESIS (2015)
Organoid Models of Human and Mouse Ductal Pancreatic Cancer
Sylvia F. Boj et al.
CELL (2015)
Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer
Sabrina Arena et al.
CLINICAL CANCER RESEARCH (2015)
EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors
Dalia Ercan et al.
CLINICAL CANCER RESEARCH (2015)
HER2-positive metastatic breast cancer: A changing scenario
G. Mustacchi et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2015)
Role of EGFR Monoclonal Antibodies in the Management of Non-small Cell Lung Cancer
Masayuki Takeda et al.
CURRENT CANCER DRUG TARGETS (2015)
Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure
Raymond Pagliarini et al.
EMBO REPORTS (2015)
Phosphorylation of Glutathione S-Transferase P1 (GSTP1) by Epidermal Growth Factor Receptor (EGFR) Promotes Formation of the GSTP1-c-Jun N-terminal kinase (JNK) Complex and Suppresses JNK Downstream Signaling and Apoptosis in Brain Tumor Cells
Tatsunori Okamura et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed
Yuliana Yosaatmadja et al.
JOURNAL OF STRUCTURAL BIOLOGY (2015)
A Phase II Trial of Gefitinib in Combination with Bevacizumab as First-Line Therapy for Advanced Non-Small Cell Lung Cancer with Activating EGFR Gene Mutations: The Okayama Lung Cancer Study Group Trial 1001
Eiki Ichihara et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer
Sara M. Tolaney et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Sandra M. Swain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The Therapeutic Challenge of Targeting HER2 in Endometrial Cancer
Elisabeth J. Diver et al.
ONCOLOGIST (2015)
Evaluation of Trastuzumab Anti-Tumor Efficacy and its Correlation with HER-2 Status in Patient-Derived Gastric Adenocarcinoma Xenograft Models
Hao Chen et al.
PATHOLOGY & ONCOLOGY RESEARCH (2015)
Comparison of the 2007 and 2013 ASCO/CAP evaluation systems for HER2 amplification in breast cancer
Xiaohong Pu et al.
PATHOLOGY RESEARCH AND PRACTICE (2015)
MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells
Dario Presutti et al.
PLOS ONE (2015)
High EMT Signature Score of Invasive Non-Small Cell Lung Cancer (NSCLC) Cells Correlates with NFκB Driven Colony-Stimulating Factor 2 (CSF2/GM-CSF) Secretion by Neighboring Stromal Fibroblasts
Albin Rudisch et al.
PLOS ONE (2015)
Impact of Modified 2013 ASCO/CAP Guidelines on HER2 Testing in Breast Cancer. One Year Experience
Zsuzsanna Varga et al.
PLOS ONE (2015)
Combination of afatinib with cetuximab in patients with EGFR-mutant non-small-cell lung cancer resistant to EGFR inhibitors
Jessica Ribeiro Gomes et al.
ONCOTARGETS AND THERAPY (2015)
Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity
Biswanath Majumder et al.
NATURE COMMUNICATIONS (2015)
Combined targeting of EGFR/HER promotes anti-tumor efficacy in subsets of KRAS mutant lung cancer resistant to single EGFR blockade
Ijeoma Adaku Umelo et al.
ONCOTARGET (2015)
Epidermal growth factor receptor mutation mediates cross-resistance to panitumumab and cetuximab in gastrointestinal cancer
Friederike Braig et al.
ONCOTARGET (2015)
Capturing complex tumour biology in vitro: histological and molecular characterisation of precision cut slices
Emma Davies et al.
SCIENTIFIC REPORTS (2015)
Butein, a Novel Dual Inhibitor of MET and EGFR, Overcomes Gefitinib-Resistant Lung Cancer Growth
Sung Keun Jung et al.
MOLECULAR CARCINOGENESIS (2015)
IGFBP7, a novel tumor stroma marker, with growth-promoting effects in colon cancer through a paracrine tumor-stroma interaction
C. Rupp et al.
ONCOGENE (2015)
Role of erbB3 receptors in cancer therapeutic resistance
Youngseok Lee et al.
ACTA BIOCHIMICA ET BIOPHYSICA SINICA (2014)
Modeling human carcinomas: Physiologically relevant 3D models to improve anti-cancer drug development
Christine Unger et al.
ADVANCED DRUG DELIVERY REVIEWS (2014)
A new tumour suppression mechanism by p27KiP1: EGFR down-regulation mediated by JNK/c-Jun pathway inhibition
Yong Fang et al.
BIOCHEMICAL JOURNAL (2014)
Three-dimensional models of cancer for pharmacology and cancer cell biology: Capturing tumor complexity in vitro/ex vivo
John A. Hickman et al.
BIOTECHNOLOGY JOURNAL (2014)
ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics
Carlos L. Arteaga et al.
CANCER CELL (2014)
One mouse, one patient paradigm: New avatars of personalized cancer therapy
Prerna Malaney et al.
CANCER LETTERS (2014)
Function-Blocking ERBB3 Antibody Inhibits the Adaptive Response to RAF Inhibitor
Curtis H. Kugel et al.
CANCER RESEARCH (2014)
HER2 aberrations in cancer: Implications for therapy
Min Yan et al.
CANCER TREATMENT REVIEWS (2014)
Association of EGFR Expression Level and Cetuximab Activity in Patient-Derived Xenograft Models of Human Non-Small Cell Lung Cancer
Christiane Amendt et al.
CLINICAL CANCER RESEARCH (2014)
Aberrant IKKα and IKKβ cooperatively activate NF-κB and induce EGFR/AP1 signaling to promote survival and migration of head and neck cancer
L. K. Nottingham et al.
ONCOGENE (2014)
Three-Dimensional Lung Tumor Microenvironment Modulates Therapeutic Compound Responsiveness In Vitro - Implication for Drug Development
Jason E. Ekert et al.
PLOS ONE (2014)
3-Dimensional Culture Systems for Anti-Cancer Compound Profiling and High-Throughput Screening Reveal Increases in EGFR Inhibitor-Mediated Cytotoxicity Compared to Monolayer Culture Systems
Amy L. Howes et al.
PLOS ONE (2014)
The ErbB/HER family of protein-tyrosine kinases and cancer
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2014)
AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
Darren A. E. Cross et al.
CANCER DISCOVERY (2014)
Oncogene addiction: resetting the safety switch?
Yulin Li et al.
ONCOTARGET (2014)
Three-Dimensional In Vitro Co-Culture Model of Breast Tumor using Magnetic Levitation
Hamsa Jaganathan et al.
SCIENTIFIC REPORTS (2014)
Activation of HER3 Interferes with Antitumor Effects of Axl Receptor Tyrosine Kinase Inhibitors: Suggestion of Combination Therapy
Robert Torka et al.
NEOPLASIA (2014)
Targeting MET Amplification as a New Oncogenic Driver
Hisato Kawakami et al.
CANCERS (2014)
The Mysterious Ways of ErbB2/HER2 Trafficking
Vibeke Bertelsen et al.
MEMBRANES (2014)
Four-membered heterocycles-containing 4-anilino-quinazoline derivatives as epidermal growth factor receptor (EGFR) kinase inhibitors
Feng Zhao et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2013)
Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor, NVP-AEW541 induces synergistic growth inhibition of human pancreatic cancer cells
Nikolaos Ioannou et al.
BMC CANCER (2013)
The S492R EGFR ectodomain mutation is never detected in KRAS wild-type colorectal carcinoma before exposure to EGFR monoclonal antibodies
Claudia Esposito et al.
CANCER BIOLOGY & THERAPY (2013)
Oncogenes induce the cancer-associated fibroblast phenotype Metabolic symbiosis and fibroblast addiction are new therapeutic targets for drug discovery
Michael P. Lisanti et al.
CELL CYCLE (2013)
An Epithelial-Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance
Lauren Averett Byers et al.
CLINICAL CANCER RESEARCH (2013)
Phase I Study of U3-1287, a Fully Human Anti-HER3 Monoclonal Antibody, in Patients with Advanced Solid Tumors
Patricia LoRusso et al.
CLINICAL CANCER RESEARCH (2013)
Three-dimensional cell culture: the missing link in drug discovery
Susan Breslin et al.
DRUG DISCOVERY TODAY (2013)
Lapatinib and doxorubicin enhance the Stat1-dependent antitumor immune response
Lara Hannesdottir et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2013)
The practicalities of using tissue slices as preclinical organotypic breast cancer models
Deborah L. Holliday et al.
JOURNAL OF CLINICAL PATHOLOGY (2013)
Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancers
Helena A. Yu et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2013)
The anti-erbB3 antibody MM-121/SAR256212 in combination with trastuzumab exerts potent antitumor activity against trastuzumab-resistant breast cancer cells
Jingcao Huang et al.
MOLECULAR CANCER (2013)
Organotypic slice cultures of human glioblastoma reveal different susceptibilities to treatments
Felicitas Merz et al.
NEURO-ONCOLOGY (2013)
Impact of the 3D Microenvironment on Phenotype, Gene Expression, and EGFR Inhibition of Colorectal Cancer Cell Lines
Anna C. Luca et al.
PLOS ONE (2013)
A Simple High-Content Cell Cycle Assay Reveals Frequent Discrepancies between Cell Number and ATP and MTS Proliferation Assays
Grace Ka Yan Chan et al.
PLOS ONE (2013)
Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer
Ron Bose et al.
CANCER DISCOVERY (2013)
Activating Mutations in HER2: Neu Opportunities and Neu Challenges
Britta Weigelt et al.
CANCER DISCOVERY (2013)
Combination therapy with anti-ErbB3 monoclonal antibodies and EGFR TKIs potently inhibits Non-small Cell Lung Cancer
Alessia Noto et al.
ONCOTARGET (2013)
A view on EGFR-targeted therapies from the oncogene-addiction perspective
Rolando Perez et al.
FRONTIERS IN PHARMACOLOGY (2013)
A High-Throughput-Compatible 3D Microtissue Co-Culture System for Phenotypic RNAi Screening Applications
Claudio R. Thoma et al.
JOURNAL OF BIOMOLECULAR SCREENING (2013)
Translation of a Tumor Microenvironment Mimicking 3D Tumor Growth Co-culture Assay Platform to High-Content Screening
Eberhard Krausz et al.
JOURNAL OF BIOMOLECULAR SCREENING (2013)
Activated human hydroxy-carboxylic acid receptor-3 signals to MAP kinase cascades via the PLC-dependent PKC and MMP-mediated EGFR pathways
Q. Zhou et al.
BRITISH JOURNAL OF PHARMACOLOGY (2012)
Toward the Prognostic Significance and Therapeutic Potential of HER3 Receptor Tyrosine Kinase in Human Colon Cancer
Abdelhamid Beji et al.
CLINICAL CANCER RESEARCH (2012)
Oncogene addiction
Jeffrey Settleman
CURRENT BIOLOGY (2012)
Targeting the EGFR signaling pathway in cancer therapy
Parthasarathy Seshacharyulu et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2012)
StellaTUM: current consensus and discussion on pancreatic stellate cell research
Mert Erkan et al.
GUT (2012)
Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors
Matthew D. Galsky et al.
INVESTIGATIONAL NEW DRUGS (2012)
Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan-Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non-Small-Cell Lung Cancer
Suresh S. Ramalingam et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Pretreatment Epidermal Growth Factor Receptor (EGFR) T790M Mutation Predicts Shorter EGFR Tyrosine Kinase Inhibitor Response Duration in Patients With Non-Small-Cell Lung Cancer
Kang-Yi Su et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
The interplay of HER2/HER3/PI3K and EGFR/HER2/PLC-γ1 signalling in breast cancer cell migration and dissemination
Lydia M. Balz et al.
JOURNAL OF PATHOLOGY (2012)
Trastuzumab anti-tumor efficacy in patient-derived esophageal squamous cell carcinoma xenograft (PDECX) mouse models
Xianhua Wu et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2012)
SKLB1206, a Novel Orally Available Multikinase Inhibitor Targeting EGFR Activating and T790M Mutants, ErbB2, ErbB4, and VEGFR2, Displays Potent Antitumor Activity Both In Vitro and In Vivo
Youli Pan et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Inhibition of doxorubicin-induced HER3-PI3K-AKT signalling enhances apoptosis of ovarian cancer cells
Martin Bezler et al.
MOLECULAR ONCOLOGY (2012)
Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer
Clara Montagut et al.
NATURE MEDICINE (2012)
BREAST CANCER HER2-a good addiction
Lisa A. Carey
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
Cyclopamine cooperates with EGFR inhibition to deplete stem-like cancer cells in glioblastoma-derived spheroid cultures
Sandrine Eimer et al.
NEURO-ONCOLOGY (2012)
Epidermal to Mesenchymal Transition and Failure of EGFR-Targeted Therapy in Glioblastoma
Andrej Pala et al.
Cancers (2012)
The ERBB network: at last, cancer therapy meets systems biology
Yosef Yarden et al.
NATURE REVIEWS CANCER (2012)
Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils
Davide Torti et al.
EMBO MOLECULAR MEDICINE (2011)
Microenvironment-Derived IL-1 and IL-17 Interact in the Control of Lung Metastasis
Yaron Carmi et al.
JOURNAL OF IMMUNOLOGY (2011)
Characterization of 64Cu-DOTA-Conatumumab: A PET Tracer for In Vivo Imaging of Death Receptor 5
Raffaella Rossin et al.
JOURNAL OF NUCLEAR MEDICINE (2011)
IBC's 21stAnnual Antibody Engineering and 8thAnnual Antibody Therapeutics International Conferences and 2010 Annual Meeting of The Antibody Society
Samantha O Arnett et al.
mAbs (2011)
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Lecia V. Sequist et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Analysis of Somatic Mutations in Cancer: Molecular Mechanisms of Activation in the ErbB Family of Receptor Tyrosine Kinases
Andrew J. Shih et al.
Cancers (2011)
Epidermal Growth Factor Receptor (EGFR) Crosstalks in Liver Cancer
Carmen Berasain et al.
Cancers (2011)
Epidermal Growth Factor Receptor in Pancreatic Cancer
Melissa Oliveira-Cunha et al.
Cancers (2011)
Comparison of Central HER2 Testing With Quantitative Total HER2 Expression and HER2 Homodimer Measurements Using a Novel Proximity-Based Assay
Weidong Huang et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2010)
HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment
Britta Weigelt et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
An Activated ErbB3/NRG1 Autocrine Loop Supports In Vivo Proliferation in Ovarian Cancer Cells
Qing Sheng et al.
CANCER CELL (2010)
Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC
Alexa B. Turke et al.
CANCER CELL (2010)
Differences underlying EGFR and HER2 oncogene addiction
Anthony C. Faber et al.
CELL CYCLE (2010)
A growing family Adding mutated Erbb4 as a novel cancer target
Udo Rudloff et al.
CELL CYCLE (2010)
The PKB/AKT Pathway in Cancer
Amancio Carnero
CURRENT PHARMACEUTICAL DESIGN (2010)
Multicellular tumor spheroids: An underestimated tool is catching up again
Franziska Hirschhaeuser et al.
JOURNAL OF BIOTECHNOLOGY (2010)
Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity
Douglas W. McMillin et al.
NATURE MEDICINE (2010)
Preparation and incubation of precision-cut liver and intestinal slices for application in drug metabolism and toxicity studies
Inge A. M. de Graaf et al.
NATURE PROTOCOLS (2010)
Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin
S. Wang et al.
ONCOGENE (2010)
Preclinical model of organotypic culture for pharmacodynamic profiling of human tumors
Valentina Vaira et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics
Dhara N. Amin et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2010)
HER2 Phosphorylation Is Maintained by a PKB Negative Feedback Loop in Response to Anti-HER2 Herceptin in Breast Cancer
Merel Gijsen et al.
PLOS BIOLOGY (2010)
Targeting of Both the c-Met and EGFR Pathways Results in Additive Inhibition of Lung Tumorigenesis in Transgenic Mice
Laura P. Stabile et al.
Cancers (2010)
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
Ji Luo et al.
CELL (2009)
Insulin-Like Growth Factor-1 Receptor Inhibition Induces a Resistance Mechanism via the Epidermal Growth Factor Receptor/HER3/AKT Signaling Pathway: Rational Basis for Cotargeting Insulin-Like Growth Factor-1 Receptor and Epidermal Growth Factor Receptor in Hepatocellular Carcinoma
Christele Desbois-Mouthon et al.
CLINICAL CANCER RESEARCH (2009)
ErbB receptors and signaling pathways in cancer
Nancy E. Hynes et al.
CURRENT OPINION IN CELL BIOLOGY (2009)
Improved reproducibility in preparing precision-cut liver tissue slices
Martina Zimmermann et al.
CYTOTECHNOLOGY (2009)
Ligand-induced ErbB receptor dimerization
Mark A. Lemmon
EXPERIMENTAL CELL RESEARCH (2009)
The EGFRvIII variant in glioblastoma multiforme
Hui K. Gan et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2009)
First-Line Gefitinib for Patients With Advanced Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Without Indication for Chemotherapy
Akira Inoue et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Spheroid-based drug screen: considerations and practical approach
Juergen Friedrich et al.
NATURE PROTOCOLS (2009)
Comparison of 3D and 2D tumor models reveals enhanced HER2 activation in 3D associated with an increased response to trastuzumab
M. Pickl et al.
ONCOGENE (2009)
Beyond Trastuzumab: Small Molecule Tyrosine Kinase Inhibitors in HER-2-Positive Breast Cancer
Vivek Roy et al.
ONCOLOGIST (2009)
Synthetic lethality: a framework for the development of wiser cancer therapeutics
William G. Kaelin
GENOME MEDICINE (2009)
Ligand-independent phosphorylation of Y869 (Y845) links mutant EGFR signaling to stat-mediated gene expression
Seungchan Yanga et al.
EXPERIMENTAL CELL RESEARCH (2008)
First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations
Lecia V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
Rafael G. Amado et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Role of ErbB4 in breast cancer
Maria Sundvall et al.
JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA (2008)
Constitutive activation of c-Jun N-terminal kinase correlates with histologic grade and EGFR expression in diffuse gliomas
Jian Yi Li et al.
JOURNAL OF NEURO-ONCOLOGY (2008)
Transforming Growth Factor-β Signaling-Deficient Fibroblasts Enhance Hepatocyte Growth Factor Signaling in Mammary Carcinoma Cells to Promote Scattering and Invasion
Nikki Cheng et al.
MOLECULAR CANCER RESEARCH (2008)
Topological Analysis of MAPK Cascade for Kinetic ErbB Signaling
Takashi Nakakuki et al.
PLOS ONE (2008)
Oncogene addiction: setting the stage for molecularly targeted cancer therapy
Sreenath V. Sharma et al.
GENES & DEVELOPMENT (2007)
STAT-mediated EGFR signaling in cancer
Kelly M. Quesnelle et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2007)
Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB Ligands and remain dependent on the ErbB receptor network
Christoph A. Ritter et al.
CLINICAL CANCER RESEARCH (2007)
Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance
Mark Barok et al.
MOLECULAR CANCER THERAPEUTICS (2007)
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Jeffrey A. Engelman et al.
SCIENCE (2007)
Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells
Bolin Liu et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Epidermal growth factor receptor mutations in lung cancer
Sreenath V. Sharma et al.
NATURE REVIEWS CANCER (2007)
Lapatinib plus capecitabine for HER2-positive advanced breast cancer
Charles E. Geyer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
A common signaling cascade may underlie addiction to the Src, BCR-ABL, and EGF receptor oncogenes
Sreenath V. Sharma et al.
CANCER CELL (2006)
Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor - Mutant lung adenocarcinomas with acquired resistance to kinase inhibitors
Marissa N. Balak et al.
CLINICAL CANCER RESEARCH (2006)
Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling
Tai W. Wong et al.
CLINICAL CANCER RESEARCH (2006)
ErbB-3 predicts survival in ovarian cancer
Berno Tanner et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Pharmacology of airways and vessels in lung slices in situ:: role of endogenous dilator hormones
L. Moreno et al.
RESPIRATORY RESEARCH (2006)
Mechanisms of Disease: oncogene addiction - a rationale for molecular targeting in cancer therapy
I. Bernard Weinstein et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2006)
Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors
Katerina Politi et al.
GENES & DEVELOPMENT (2006)
The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies
Hongbin Ji et al.
CANCER CELL (2006)
Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors
Hongbin Ji et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer
A Lièvre et al.
CANCER RESEARCH (2006)
Short term culture of breast cancer tissues to study the activity of the anticancer drug taxol in an intact tumor environment
H van der Kuip et al.
BMC CANCER (2006)
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
N Thatcher et al.
LANCET (2005)
Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations
T Mukohara et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib
EL Kwak et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Small molecules with EGFR-TK inhibitor activity
J Albanell et al.
CURRENT DRUG TARGETS (2005)
Amplification of HER-2 in gastric carcinoma:: association with Topoisomerase IIα gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab
M Tanner et al.
ANNALS OF ONCOLOGY (2005)
The concept of synthetic lethality in the context of anticancer therapy
WG Kaelin
NATURE REVIEWS CANCER (2005)
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib
W Pao et al.
PLOS MEDICINE (2005)
Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex
MC Franklin et al.
CANCER CELL (2004)
Desmoplastic reaction in pancreatic cancer - Role of pancreatic stellate cells
MV Apte et al.
PANCREAS (2004)
EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib
W Pao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways
R Sordella et al.
SCIENCE (2004)
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
Y Nagata et al.
CANCER CELL (2004)
Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase
SK Rabindran et al.
CANCER RESEARCH (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Gefitinib (Iressa) in oncogene-addictive cancers and therapy for common cancers
MV Blagosklonny
CANCER BIOLOGY & THERAPY (2004)
Dual kinase inhibition in the treatment of breast cancer: Initial experience with the EGFR/ErbB-2 inhibitor lapatinib
HA Burris
ONCOLOGIST (2004)
Prognostic value of ERBB family mRNA expression in breast carcinomas
I Bièche et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
A computational model on the modulation of mitogen-activated protein kinase (MAPK) and Akt pathways in heregulin-induced ErbB signalling
M Hatakeyama et al.
BIOCHEMICAL JOURNAL (2003)
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer
M Fukuoka et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
The ErbB receptors and their role in cancer progression
T Holbro et al.
EXPERIMENTAL CELL RESEARCH (2003)
Comparison of in vitro preparations for semi-quantitative prediction of in vivo drug metabolism
IAM De Graaf et al.
DRUG METABOLISM AND DISPOSITION (2002)
Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways
WL Xia et al.
ONCOGENE (2002)
Engineering cellular microenvironments to cell-based drug testing improve
K Bhadriraju et al.
DRUG DISCOVERY TODAY (2002)
Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer
FJ Esteva et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Tumor biology - Herceptin acts as an anti-angiogenic cocktail
Y Izumi et al.
NATURE (2002)
Epidermal growth factor receptor biology (IMC-C225)
ES Kim et al.
CURRENT OPINION IN ONCOLOGY (2001)
An essential role for Src kinase in ErbB receptor signaling through the MAPK pathway
MA Olayioye et al.
EXPERIMENTAL CELL RESEARCH (2001)
Akt, MAPK (Erk1/2), and p38 act in concert to promote apoptosis in response to ErbB receptor family inhibition
JM Nelson et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Untangling the ErbB signalling network
Y Yarden et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2001)
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
RA Clynes et al.
NATURE MEDICINE (2000)
Marked inhibition of glioblastoma target cell tumorigenicity in vitro by retrovirus-mediated transfer of a hairpin ribozyme against deletion-mutant epidermal growth factor receptor messenger RNA
ME Halatsch et al.
JOURNAL OF NEUROSURGERY (2000)
Epithelial mesenchymal transition by c-Fos estrogen receptor activation involves nuclear translocation of β-catenin and upregulation of β-catenin/lymphoid enhancer binding factor-1 transcriptional activity
A Eger et al.
JOURNAL OF CELL BIOLOGY (2000)
Share Paper
